Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 1/20 | 0.54 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | PIP4K2A | P48426 | 4/20 | 0.40 |
| ▸ | PIP4K2B | P78356 | 4/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL749641 | 0.81 | SLC22A12 (0.47) | SLC22A12ALPL | |
| SCHEMBL3119732 | 0.80 | SLC22A12 (0.46) | PIK3CBSLC22A12PTGS2PTGS1ALPL | |
| SCHEMBL3093140 | 0.80 | ALDH1A1 (0.47) | SLC22A12 | |
| SCHEMBL10252851 | 0.78 | PIK3CB (0.56) | PIK3CBSLC22A12PTGS2PTGS1DYRK1A | |
| SCHEMBL18424076 | 0.77 | PIK3CB (0.54) | PIK3CBSLC22A12PTGS2PTGS1DYRK1A | |
| SCHEMBL20461929 | 0.77 | PIK3CB (0.54) | PIK3CBPTGS1DYRK1AKEAP1PIP4K2A | |
| Ethanesulfonic Acid Amide SCHEMBL1607974 | 0.76 | SLC22A12 (0.43) | PIK3CBSLC22A12ALPL | |
| SCHEMBL12147001 | 0.76 | PIK3CB (0.53) | PIK3CBDYRK1AKEAP1PIP4K2APIP4K2B | |
| SCHEMBL783676 | 0.75 | SLC22A12 (0.45) | SLC22A12PTGS2PTGS1ALPL | |
| SCHEMBL1621978 | 0.75 | PIK3CB (0.60) | PIK3CBSLC22A12PTGS2ALPLNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116878-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20240116927-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2024-04-11 | — | — | US | disclosed |
| EP-4335512-A2 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HiberCell, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3728217-B1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3728217-B1 | CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL PHOSPHATE KINASE INHIBITORS | HIBERCELL INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | HIBERCELL, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | TENARX, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-2303890-A2 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | Progenics Pharmaceuticals, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2280946-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | Glaxo Group Limited (GB) | 2011-02-09 | — | — | EP | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009155527-A9 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009155527-A9 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009155527-A2 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155527-A2 | PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009147187-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009147187-A1 | 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | PIK3CB 9/4885SLC22A12 1522/4885PTGS2 1286/4885 |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | PIK3CB 904/4885SLC22A12 3261/4885PTGS2 1413/4885 |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | PIK3CB 904/4885SLC22A12 3261/4885PTGS2 1413/4885 |
| US-11584763-B2 | Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors | PIP5K1A, PIP5K1B, PI4KA | PIK3CB 14/4885SLC22A12 4554/4885PTGS2 2611/4885 |
| US-20240116927-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | PIK3CB 904/4885SLC22A12 3261/4885PTGS2 1413/4885 |
| US-20260116878-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | PIK3CB 2313/4885SLC22A12 3481/4885PTGS2 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.